Literature DB >> 15681442

Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages.

Victoria Wahl-Jensen1, Sabine K Kurz, Paul R Hazelton, Hans-Joachim Schnittler, Ute Ströher, Dennis R Burton, Heinz Feldmann.   

Abstract

Ebola virus, a member of the family Filoviridae, causes one of the most severe forms of viral hemorrhagic fever. In the terminal stages of disease, symptoms progress to hypotension, coagulation disorders, and hemorrhages, and there is prominent involvement of the mononuclear phagocytic and reticuloendothelial systems. Cells of the mononuclear phagocytic system are primary target cells and producers of inflammatory mediators. Ebola virus efficiently produces four soluble glycoproteins during infection: sGP, delta peptide (Delta-peptide), GP(1), and GP(1,2Delta). While the presence of these glycoproteins has been confirmed in blood (sGP) and in vitro systems, it is hypothesized that they are of biological relevance in pathogenesis, particularly target cell activation. To gain insight into their function, we expressed the four soluble glycoproteins in mammalian cells and purified and characterized them. The role of the transmembrane glycoprotein in the context of virus-like particles was also investigated. Primary human macrophages were treated with glycoproteins and virus-like particles and subsequently tested for activation by detection of several critical proinflammatory cytokines (tumor necrosis factor alpha, interleukin-6 [IL-6], and IL-1 beta) and the chemokine IL-8. The presentation of the glycoprotein was determined to be critical since virus-like particles, but not soluble glycoproteins, induced high levels of activation. We propose that the presentation of GP(1,2) in the rigid form such as that observed on the surface of particles is critical for initiating a sufficient signal for the activation of primary target cells. The secreted glycoproteins do not appear to play any role in exogenous activation of these cells during Ebola virus infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681442      PMCID: PMC546544          DOI: 10.1128/JVI.79.4.2413-2419.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer.

Authors:  V A Volchkova; H Feldmann; H D Klenk; V E Volchkov
Journal:  Virology       Date:  1998-10-25       Impact factor: 3.616

2.  Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain.

Authors:  W Weissenhorn; A Carfí; K H Lee; J J Skehel; D C Wiley
Journal:  Mol Cell       Date:  1998-11       Impact factor: 17.970

Review 3.  Processing of the Ebola virus glycoprotein.

Authors:  V E Volchkov
Journal:  Curr Top Microbiol Immunol       Date:  1999       Impact factor: 4.291

4.  The reovirus mutant tsA279 L2 gene is associated with generation of a spikeless core particle: implications for capsid assembly.

Authors:  P R Hazelton; K M Coombs
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

5.  The central structural feature of the membrane fusion protein subunit from the Ebola virus glycoprotein is a long triple-stranded coiled coil.

Authors:  W Weissenhorn; L J Calder; S A Wharton; J J Skehel; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

6.  Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates.

Authors:  A Sanchez; T G Ksiazek; P E Rollin; M E Miranda; S G Trappier; A S Khan; C J Peters; S T Nichol
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

7.  Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages.

Authors:  H Feldmann; H Bugany; F Mahner; H D Klenk; D Drenckhahn; H J Schnittler
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Release of viral glycoproteins during Ebola virus infection.

Authors:  V E Volchkov; V A Volchkova; W Slenczka; H D Klenk; H Feldmann
Journal:  Virology       Date:  1998-05-25       Impact factor: 3.616

9.  Biochemical analysis of the secreted and virion glycoproteins of Ebola virus.

Authors:  A Sanchez; Z Y Yang; L Xu; G J Nabel; T Crews; C J Peters
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

10.  T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction?

Authors:  M F Bachmann; H Hengartner; R M Zinkernagel
Journal:  Eur J Immunol       Date:  1995-12       Impact factor: 5.532

View more
  58 in total

1.  Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function.

Authors:  Victoria M Wahl-Jensen; Tatiana A Afanasieva; Jochen Seebach; Ute Ströher; Heinz Feldmann; Hans-Joachim Schnittler
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  Filovirus replication and transcription.

Authors:  Elke Mühlberger
Journal:  Future Virol       Date:  2007-03       Impact factor: 1.831

Review 3.  Ebola Vaccine: How Far are we?

Authors:  Rajani Sharma; Ketki Jangid
Journal:  J Clin Diagn Res       Date:  2017-05-01

4.  An Improved Reverse Genetics System to Overcome Cell-Type-Dependent Ebola Virus Genome Plasticity.

Authors:  Yoshimi Tsuda; Thomas Hoenen; Logan Banadyga; Carla Weisend; Stacy M Ricklefs; Stephen F Porcella; Hideki Ebihara
Journal:  J Infect Dis       Date:  2015-03-24       Impact factor: 5.226

Review 5.  Characterization of a putative filovirus vaccine: virus-like particles.

Authors:  Karen A O Martins; Travis K Warren; Sina Bavari
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

6.  Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection.

Authors:  Yoshimi Tsuda; David Safronetz; Kyle Brown; Rachel LaCasse; Andrea Marzi; Hideki Ebihara; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

7.  Inhibition of Ebola virus glycoprotein-mediated cytotoxicity by targeting its transmembrane domain and cholesterol.

Authors:  Moritz Hacke; Patrik Björkholm; Andrea Hellwig; Patricia Himmels; Carmen Ruiz de Almodóvar; Britta Brügger; Felix Wieland; Andreas M Ernst
Journal:  Nat Commun       Date:  2015-07-09       Impact factor: 14.919

8.  Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects.

Authors:  Luis M Branco; Jessica N Grove; Lina M Moses; Augustine Goba; Mohammed Fullah; Mambu Momoh; Randal J Schoepp; Daniel G Bausch; Robert F Garry
Journal:  Virol J       Date:  2010-11-09       Impact factor: 4.099

9.  Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding.

Authors:  Megan M Illick; Luis M Branco; Joseph N Fair; Kerry A Illick; Alex Matschiner; Randal Schoepp; Robert F Garry; Mary C Guttieri
Journal:  Virol J       Date:  2008-12-23       Impact factor: 4.099

10.  Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms.

Authors:  Luis M Branco; Robert F Garry
Journal:  Virol J       Date:  2009-09-24       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.